Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...

Full Year 2024 Results Key Financial Results Revenue: US$128.9m (up by ...

Stifel Nicolaus analyst Benjamin Burnett maintained a Hold rating on Atara Biotherapeutics (ATRA – Research Report) yesterday and set a price ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Atara Biotherapeutics (ATRA – Research Report) yesterday. The company’s shares closed ...

THOUSAND OAKS, Calif. (AP) — THOUSAND OAKS, Calif. (AP) — Atara Biotherapeutics Inc. (ATRA) on Friday reported a loss of $12.7 million in its fourth quarter. The Thousand Oaks, California-based ...

Atara is working closely with its partners ... preserve resources Strategic review by financial advisor ongoing Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy ...

Atara Biotherapeutics said it would lay off half of its workforce in a restructuring that came as the company narrowed its loss and logged higher revenue in the fourth quarter. The immunotherapy ...

Atara Biotherapeutics is halving its headcount as it navigates the fallout from the FDA’s move to halt trials of the ...

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report) have been given a consensus rating of “Moderate Buy” by the seven analysts that are currently covering the firm, MarketBeat.com ...

Less than two months after two FDA-related setbacks, Atara Biotherapeutics is again cutting its workforce in half. This time, ...

--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative ...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...